Developing breakthrough AXL therapeutics to improve patients’ lives
SCIENTIFIC PUBLICATIONS
Cell Report Medicine, Huiyu Li et al.
15th March 2022
AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells
BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases including cancer and severe respiratory infections
BerGenBio’s lead candidate, bemcentinib, is in Phase II clinical testing in patients with NSCLC, AML and COVID-19. As of the end of 2021, bemcentinib had been studied in over 600 patients, demonstrating its safety as a monotherapy and in combination with chemotherapy and immune checkpoint inhibition. This large safety database positions us well to advance the development of bemcentinib towards the market. Clinical data generated with bemcentinib in multiple Phase I and Phase II trials to date, confirm its potential utility as a therapy in cancer and for the treatment of COVID-19. Based on preclinical and early clinical data, we also believe bemcentinib may have the ability to enhance outcomes when combined with immunotherapy in NSCLC. Taken together, our initial data form the basis of BerGenBio’s preparations for the late-stage clinical strategy for bemcentinib.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (OSE:BGBIO).
Explore BerGenBio’s pipelineEdison interview with our CEO
Martin Olin March 2022
Latest News
BERGENBIO PRESENTS CLINICAL DATA ON BEMCENTINIB IN COMBINATION WITH DOCETAXEL IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NSCLC AT ASCO ANNUAL MEETING 2022
Bergen, Norway, 6 June 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, is pleased to announce presentation of a
Read moreBERGENBIO ASA: RESULTS FOR THE FIRST QUARTER 2022
Bergen, Norway, 24 May 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announces its results for
Read moreBERGENBIO ANNOUNCES LAUNCH OF BUSINESS STRATEGY FOCUSED ON NSCLC AND COVID-19
BerGenBio to focus on two key opportunities for its lead compound bemcentinib Strategic focus anchored in strong scientific rationale, supported by dataset from over 600 patients demonstrating bemcentinib’s biological
Read moreBERGENBIO ANNOUNCES COMPLETE DATA ANALYSIS OF ACCORD2 PHASE II BEMCENTINIB STUDY IN HOSPITALIZED COVID-19 PATIENTS – PRIMARY EFFICACY ENDPOINT MET
Complete data analysis confirms that the primary endpoint of improved clinical response and key secondary endpoints were met in a subprotocol under the platform ACCORD2 study where bemcentinib was
Read more
